Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences

Overview of attention for article published in Hereditary Cancer in Clinical Practice, January 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 18,821 followers.

RT @LguzzardiM: Recontacting non BRCA #breastcancer patients for germline #CHEK2 c.1100del pathogenic variant #genetictesting : uptake and…

RT @LguzzardiM: Recontacting non BRCA #breastcancer patients for germline #CHEK2 c.1100del pathogenic variant #genetictesting : uptake and…

RT @LguzzardiM: Recontacting non BRCA #breastcancer patients for germline #CHEK2 c.1100del pathogenic variant #genetictesting : uptake and…

Recontacting non BRCA #breastcancer patients for germline #CHEK2 c.1100del pathogenic variant #genetictesting : uptake and patient experiences. #bcsm #hereditarycancer #genetics #cancerresearch https://t.co/irRFHvw2IE

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.